Next Article in Journal
Immune Functions of Astrocytes in Viral Neuroinfections
Next Article in Special Issue
Insights into the Molecular Mechanisms of NRF2 in Kidney Injury and Diseases
Previous Article in Journal
Vitamin D Receptor Mediates Attenuating Effect of Lithocholic Acid on Dextran Sulfate Sodium Induced Colitis in Mice
Previous Article in Special Issue
Toll-like Receptor 4 in Acute Kidney Injury
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 4
10.3390/ijms24043518
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Pre-Treatment of Transplant Donors with Hydrogen Sulfide to Protect against Warm and Cold Ischemia-Reperfusion Injury in Kidney and Other Transplantable Solid Organs

by
Liam McFarlane
1,2,†,
Pierce Nelson
1,2,†,
George J. Dugbartey
1,3,4,5 and
Alp Sener
1,2,3,4,*
1
Matthew Mailing Center for Translational Transplant Studies, London Health Sciences Center, Western University, London, ON N6A 5A5, Canada
2
Department of Microbiology & Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON N6A 5C1, Canada
3
Department of Surgery, Division of Urology, London Health Sciences Center, Western University, London, ON N6A 5A5, Canada
4
Multi-Organ Transplant Program, London Health Sciences Center, University Hospital, London, ON N6A 5A5, Canada
5
Department of Pharmacology and Toxicology, School of Pharmacy, College of Health Sciences, University of Ghana, Legon, Accra P.O. Box LG43, Ghana
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2023, 24(4), 3518; https://doi.org/10.3390/ijms24043518
Submission received: 5 January 2023 / Revised: 1 February 2023 / Accepted: 7 February 2023 / Published: 9 February 2023
(This article belongs to the Special Issue New Insights into the Molecular Mechanisms of Kidney Injury and Repair)
Browse Figures
Versions Notes

Abstract

:
Ischemia-reperfusion injury (IRI), a pathological condition resulting from prolonged cessation and subsequent restoration of blood flow to a tissue, is an inevitable consequence of solid organ transplantation. Current organ preservation strategies, such as static cold storage (SCS), are aimed at reducing IRI. However, prolonged SCS exacerbates IRI. Recent research has examined pre-treatment approaches to more effectively attenuate IRI. Hydrogen sulfide (H2S), the third established member of a family of gaseous signaling molecules, has been shown to target the pathophysiology of IRI and thus appears to be a viable candidate that can overcome the transplant surgeon’s enemy. This review discusses pre-treatment of renal grafts and other transplantable organs with H2S to mitigate transplantation-induced IRI in animal models of transplantation. In addition, ethical principles of pre-treatment and potential applications of H2S pre-treatment in the prevention of other IRI-associated conditions are discussed.

1. Introduction

Solid organ transplantation (SOT) is the preferred therapy for end-stage organ disease. Despite its benefits, the long-term success of SOT is hampered by the incidence of ischemia-reperfusion injury (IRI). IRI is an inevitable pathological condition resulting from temporary cessation of blood flow to a tissue (warm ischemia) during graft procurement, followed by hypothermic preservation (cold ischemia) and restoration of blood flow (reperfusion) during transplantation of the graft [1]. Current mitigation strategies against IRI include static cold storage (SCS) of organ grafts at 4 °C in clinically standard preservation solutions, such as the University of Wisconsin (UW) solution [2]. While SCS is effective in reducing the metabolic demand of the graft and thereby minimizing the extent of IRI and keeping the graft in a usable state, development of IRI remains unavoidable [3]. The duration of ischemic cold storage correlates with delayed graft function (DGF) and reduced long-term survival of the grafts [4,5,6]. This necessitates the swift usage of organ grafts and as a result, thousands of organs are discarded each year [7]. This clinical problem suggests that better preservation techniques are needed to improve graft quality and help combat the global donor organ shortage crisis [7]. Many additional strategies to mitigate IRI in SOT have been proposed and tested in experimental models [3]. These include the pharmacological modification of organ preservation solutions, ischemic preconditioning (brief periods of ischemia to protect against subsequent long ischemic periods), and mechanical perfusion [8,9,10,11]. In particular, the strategy of pre-treating donor organs before procurement has gained credit as a prospective solution. A study by Niemann et al. [12] enrolled 394 kidney donors after neurological death to investigate the role of mild hypothermic (34–35 °C) pre-treatment on renal transplant outcomes. Body temperature of neurologically deceased donors was either actively maintained at 37 °C as a control or cooled to 34 °C, with these target temperatures being maintained until organ procurement. Interestingly, the rate of DGF was significantly lower in transplanted kidneys from the hypothermic group. Another trial investigating the potential of pre-treatment is currently underway in Canada, where neurologically deceased kidney donors are administered tacrolimus, a calcineurin inhibitor, intravenously 4–8 h before organ procurement [13]. The goal of this pilot trial is to determine the effectiveness of tacrolimus pre-treatment on reducing DGF through protection against IRI. Pre-treatment with other pharmacological agents, such as hydrogen sulfide (H2S) are currently being investigated with the goal of limiting IRI and reducing the occurrence of DGF. The clinical potential of H2S pre-treatment in SOT is considerable. Pre-treatment could be easily paired with either of the two most widely used mitigation strategies, SCS and machine perfusion. Extending beyond pre-treatment, the inclusion of H2S in the SCS preservation solution and mechanically perfused solution has been shown by our research group to benefit these respective strategies in a renal transplantation model [14,15]. In this review, we discuss the concept of treating donor animals with H2S before their organs are harvested for transplantation into recipient animals.

2. Cellular Mechanisms Underlying Ischemia-Reperfusion Injury in SOT

IRI can occur in various organs and tissues, commonly resulting from medical procedures, including SOT. In general, IRI is characterized by oxidative stress, inflammation, mitochondrial dysfunction, and cell death primarily via necrosis or apoptosis [16,17]. However, there are certain tissue-specific characteristics of IRI that usually reflect the function of the organ in which IRI occurs [17]. The lack of perfusion to a tissue generates a hypoxic environment in the tissue. The reduction of available oxygen encourages anaerobic respiration, leading to a dramatic decrease in ATP production accompanied by a decrease in cell pH [18] (Figure 1). The high intracellular proton concentration promotes the activity of the Na+/H+ exchanger, which along with the arrest of the Na+/K+ ATPase, generates an elevated intracellular Na+ concentration [8]. The accumulation of cytosolic Ca2+ ensues due to the arrest of the ATP-dependent calcium export and the reduction in the activity of the Na+/Ca2+ exchanger [8]. As a result, mitochondrial Ca2+ transport is increased, resulting in elevated mitochondrial Ca2+ concentration [19]. Mitochondria play a critical role in the pathogenesis of IRI. During prolonged ischemic periods, protein complexes of the electron transport chain (ETC) are impaired, leading to decreased ATP production and increased electron leak [20,21]. Electron leak is responsible for the production of superoxide (O2−), which is normally eliminated through oxidation by mitochondrial superoxide dismutase (MnSOD) to H2O2 and subsequent oxidation to H2O by glutathione peroxidases, catalase, or peroxiredoxins [22]. This basal level of reactive oxygen species (ROS) generation is exacerbated during reperfusion, the effector phase of ischemic injury, where rapid oxidation of accumulated succinate by reverse action of the ETC drives massive ROS generation [23]. The overproduction of ROS overwhelms antioxidant enzyme activity and further contributes to ROS accumulation [24]. The resultant elevated ROS and increased mitochondrial Ca2+ concentration lead to the opening of the mitochondrial permeability transition pores (mPTPs) [24]. Opening of the mPTPs causes the uncoupling of oxidative phosphorylation and the release of pro-apoptotic factors into the cytoplasm and nucleus, leading to apoptosis [19]. Increased levels of inorganic phosphate, depletion of adenosine nucleotides, and rapid pH restoration upon reperfusion also contribute to mPTP opening and further cell death by apoptosis [25]. In addition to apoptosis, cell death in IRI occurs through autophagy and various forms of regulated necrosis, such as necroptosis and ferroptosis [26,27,28]. Necroptosis in particular is a major contributor to cell death in IRI, as evidenced by the protective effects of necrostatin-1 (inhibitor of necroptosis) against renal IRI [26]. Necroptosis and a more recently discovered form of regulated necrosis called ferroptosis appear to be the most prominent causes of necrotic cell death in IRI [27,29]. Cell death via necrosis induces the release of danger-associated molecular patterns (DAMPs) into the extracellular space that are normally sequestered inside the cell [30]. DAMPs, as well as ROS, induce the production of pro-inflammatory cytokines, chemokines, and the expression of endothelial adhesion molecules [18,31]. This inflammatory response causes the accumulation of neutrophils, macrophages, CD4+ T cells, and other immune cells in the affected tissue [18,19]. Neutrophils exacerbate cell death via the deposition of pore-forming proteins onto affected cells. Additionally, IRI induces complement activation, which further contributes to cell death and inflammation [32]. Autophagy is another form of cell death that has a unique role in the pathogenesis of IRI. It has been shown that autophagy confers protection to cells during ischemia, perhaps by providing the cell energy in the form of degraded cellular components [28]. In prolonged ischemia, however, catabolism exceeds anabolism and thus autophagy contributes to cell death [28]. Collectively, IRI induces significant cell death, ROS formation, and inflammation.

3. H2S and Its Endogenous Production

H2S is an established member of a family of small endogenously produced gaseous signaling molecules referred to as gasotransmitters [15,33]. This family of gaseous signaling molecules, which also includes carbon monoxide (CO) and nitric oxide (NO), plays an important role in cellular homeostasis and are being experimentally investigated in the context of organ transplantation [15,33]. H2S is endogenously produced via three enzymes: cystathionine beta-synthase (CBS) [34,35], cystathionine γ-lyase (CSE) [36], and 3-mercaptopyruvate sulfurtransferase (3MST) [37,38]. Both CBS and CSE are cytosolic enzymes and produce H2S using the amino acid L-cysteine as their substrate [34,35,36], whereas 3MST, a mitochondrial enzyme, uses 3-mercaptopyruvate (3MP) as a substrate [37,38]. In turn, 3MP may be generated via cysteine aminotransferase with α-ketoglutarate and cysteine used as substrates [38] or via D-amino acid oxidase (DAO) with D-cysteine used as a substrate [37].
Historically, H2S was recognized as both a human and environmental toxin [39]. At high concentrations, it inhibits complex IV of the mitochondrial ETC, which suppresses cellular proliferation and metabolism while inducing apoptosis [40,41]. However, research on H2S over the past several years has shown that H2S is an important gaseous signaling molecule with biological usefulness and therapeutic potential [39,42]. In addition to direct inhalation of the gas, H2S donors have been recognized as compounds that can release gaseous H2S in response to specific stimuli [33]. Exogenous administration of several H2S donors has shown great therapeutic promise in the context of IRI, such as sodium sulfide (Na2S), sodium hydrosulfide (NaHS), GYY4137, AP39, and sodium thiosulfate (STS) [15,43,44,45,46,47,48,49,50,51,52]. Our research group recently reviewed the use of H2S donors in models of transplantation-induced cold IRI [1]. These studies have largely focused on treating organs with H2S donors during ischemia (ischemic treatment) or after reperfusion (post-treatment). Ischemic treatment and post-treatment approaches have been shown to protect against IRI involving the brain, heart, intestine, kidneys, lungs, and pancreas [15,43,44,45,46,47,48,49,50,51,52]. The mechanisms of this protection include suppressing oxidative stress, cell death, pro-inflammatory responses, or a combination of these processes (Table 1) [15,43,44,45,46,47,48,49,50,51,52]. However, a more limited body of research has investigated the effect of pre-treating organs with H2S prior to ischemia (pre-treatment).

4. H2S Pre-Treatment against Cold IRI

Currently, there is a very limited body of research focused on the use of exogenous H2S pre-treatment in the context of cold IRI induced by SOT. To our knowledge, only two studies have examined the effect of exogenous H2S pre-treatment in models of cold IRI. Both studies have focused on lung transplantation (Figure 2).

4.1. H2S Pre-Treatment against Cold IRI in Lung Transplantation

In one study, male New Zealand white rabbits either inhaled room air supplemented with gaseous H2S or room air alone for two hours prior to their lungs and heart being harvested for en bloc heart-lung transplantation [53]. The heart-lung grafts were stored in preservation solution at 4 °C for 18 h, after which they were ventilated and perfused with blood from donor rabbits for two hours. The researchers found that during reperfusion, heart-lung blocs from rabbits pre-treated with H2S exhibited better pulmonary function as evidenced by improved oxygenation and ventilation. While ROS levels did not differ in lung biopsies taken from either the H2S pre-treated or control groups before SCS of the heart-lung blocs in preservation solution, ROS levels were significantly lower in lung biopsies taken during reperfusion in the H2S pre-treated group. This antioxidant effect of H2S during reperfusion is particularly important since most ROS production occurs during the reperfusion phase of IRI due to the reverse action of complex I of the ETC [23]. Interestingly, complex IV activity was significantly higher in biopsies taken from lungs in the H2S pre-treatment group after SCS but before reperfusion [53]. This finding may seem contradictory to the known inhibitory effect of H2S on complex IV of the ETC [40]. However, since H2S can also act as an electron donor to the ETC [54], H2S may have supported complex IV activity by donating electrons to the ETC to maintain ATP production during ischemia [53]. Another possible explanation is that apoptosis may have been higher in heart-lung blocs from the control group, which would have lowered complex IV activity, since apoptosis leads to the release of complex IV [53,55].
In a more recent study by Meng et al. [56] involving donation after circulatory death (DCD) lung transplantation in male Sprague Dawley rats, the researchers either deflated the lungs or inflated the lungs with air containing gaseous H2S or air alone for two hours. During this period of warm ischemia, lungs inflated with H2S had a lower metabolic rate relative to the control lungs, which aligns with a previous study that showed H2S can induce a hypometabolic state in mice [41]. The left lungs were then harvested and stored in preservation solution at 4 °C for 3 h followed by syngeneic transplantation into recipient rats, where reperfusion occurred for 3 h [56]. Interestingly, lungs that were inflated with H2S showed enhanced pulmonary function along with reduced apoptosis, inflammation, and oxidative stress. To understand the anti-inflammatory and antioxidant effects of H2S pre-treatment, the researchers examined the translocation of both nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and nuclear factor erythroid 2-related factor 2 (Nrf2) from the cytoplasm to the nucleus. NF-κB is a well-recognized transcription factor that is normally inhibited in the cytoplasm, but upon activation is translocated to the nucleus where it can upregulate the expression of pro-inflammatory genes [57]. Nrf2 is a transcription factor normally degraded in the cytoplasm but is stabilized under oxidative stress, which enables Nrf2 to translocate to the nucleus and upregulate the expression of genes involved in cellular protection [58]. As would be expected, NF-κB nuclear translocation was lower and Nrf2 nuclear translocation was higher in biopsies obtained from lungs that were inflated with gaseous H2S [56]. In summary, these two studies demonstrate that H2S pre-treatment of lung donors protects transplanted lung grafts from IRI through the suppression of apoptosis, inflammation, and oxidative stress, likely via modulation of NF-κB and Nrf2 nuclear localization.

4.2. H2S Pre-Treatment against Cold IRI in Kidney Transplantation

Although no studies have examined the impact of H2S pre-treatment in the context of cold IRI in kidney transplantation, a previous study showed that endogenous H2S production in kidney donors is associated with improved kidney function in recipients after kidney transplantation [59]. Specifically, the expression of CSE at the time of kidney graft procurement was positively associated with the glomerular filtration rate 14 days following transplantation in humans. Although this is not an example of exogenous H2S donor pre-treatment, this study suggests that higher levels of H2S in kidney transplant donors prior to graft procurement may protect kidney grafts against IRI, leading to enhanced kidney function in recipients after transplantation.

5. H2S Pre-Treatment against Warm IRI

Much of the research concerned with the effect of H2S pre-treatment on IRI to date has been carried out in the context of warm IRI. Although cold IRI is of considerably longer duration, warm IRI remains an inevitable consequence of SOT (Figure 1). In addition to SOT, warm IRI has implications in many other surgical procedures and pathological conditions. While pre-treatment using an agent effectively protective against warm IRI would be a tremendous asset in preventing surgically induced IRI, the unpredictable onset of ischemia in pathological conditions makes pre-treatment a less practical option. In the following section, the literature concerning the effects of H2S pre-treatment against warm IRI in transplantable organs will be discussed.

5.1. H2S Pre-Treatment against Warm Renal IRI

Renal IRI is a major cause of acute kidney injury (AKI) [60]. A study by Bos et al. [61] showed that inhalation of H2S gas prior to and during the induction of renal ischemia (which the authors referred to as pretreatment) protected mouse kidneys. In their observations, renal protection following pre-treatment with H2S was characterized by reduced apoptosis, inflammation, and histopathological changes. This renal protection resulted in improved renal function (as measured by serum creatinine) compared to mice that received gaseous H2S beginning immediately before reperfusion and the control group [61]. This protective effect of H2S can be attributed to the induction of hypometabolism [61] as well as the suppression of oxidative stress, reduced intracellular adhesion molecule 1 (ICAM-1) expression, and increased Nrf2 nuclear translocation [62,63,64]. The protective effects of H2S against warm renal IRI observed in this study cannot be attributed to pretreatment alone due to the continuation of H2S inhalation into the ischemic period. Still, these findings provide insight into the prospective usefulness of H2S pretreatment as a novel strategy to mitigate the induction of AKI in clinical settings. Utilizing H2S as a protective therapeutic would prove especially valuable in major surgical procedures (such as cardiac surgery), contrast dye administration, and patients with sepsis, all of which are major causes of AKI [65,66]. It could also be extended to experimental and clinical kidney transplantation in which kidney donors could be treated with H2S donors prior to renal graft procurement, during which a brief period of warm ischemia occurs. A summary of studies involving pre-treatment with H2S in cold and warm IRI is provided below in Table 2.

5.2. H2S Pre-Treatment against Warm Myocardial IRI

Warm myocardial IRI is an inevitable consequence of the restoration of blood flow following myocardial infarction (MI) and contributes to an estimated 50% of the resultant infarct size [25,67]. A significant body of research has assessed the cardioprotective potential of H2S pre-treatment against warm myocardial IRI. Sivarajah et al. [68] pre-treated rats with the H2S donor NaHS 15 min prior to left anterior descending coronary artery occlusion and subsequent reperfusion. Compared to the control, they observed a significant reduction in infarct size and attenuation of apoptosis, caspase 9 activity, NF-kB nuclear translocation, oxidative stress, myeloperoxidase activity, and neutrophil infiltration in the cardiomyocytes of the NaHS-treated group. In a similar study, pre-treatment with NaHS resulted in a more significant reduction in infarct size than NaHS post-treatment [69]. H2S pre-treatment could also be especially valuable in diabetes mellitus patients, who are at increased risk for myocardial ischemia and its associated mortality [70]. In db/db mice, the cardioprotective effect of H2S pre-treatment against myocardial IRI has been described [71]. Taken together, the cardioprotective effects of H2S pre-treatment in these experimental models demonstrate the need for further research on the potential of clinically viable H2S donor molecules in attenuating the damage induced by myocardial IRI. Since warm IRI also occurs during SOT, further research could provide a clinical rationale for pre-treating heart donors with H2S prior to heart procurement.

5.3. H2S Pre-Treatment against Warm Hepatic IRI

Ischemia-reperfusion injury is the most common cause of liver dysfunction following liver surgery [72]. Zhang et al. [73] demonstrated that the administration of NaHS to rats 5 min before the induction of hepatic ischemia reduced levels of necrotic, mitochondrial-related, and apoptotic cell death. The authors attributed this protective effect to the inhibition of mPTP opening and activation of Akt-GSK-3β signaling in hepatocytes. A similar study by Cheng et al. [74] also found NaHS to have a protective effect against hepatic IRI. In this study, NaHS was shown to reduce the expression of the pro-inflammatory cytokines TNF-α and IL-6 in addition to diminishing apoptotic cell death via the inhibition of JNK1 signaling. The protective effects of H2S against hepatic IRI in these models demonstrate the potential clinical utility of H2S administration preceding surgical procedures known to induce warm IRI in the liver, such as liver transplantation.

5.4. H2S Pre-Treatment against Warm Intestinal IRI

Intestinal IRI can result from necrotizing enterocolitis, midgut volvulus, intussusception, adhesive intestinal obstruction, sepsis, and hemodynamic shock [75]. Surgical induction of intestinal IRI is also seen as a consequence of cardiac surgery and liver or intestinal transplantation [76]. Protection against intestinal IRI was observed after H2S pre-treatment in a study by Liu et al. [77]. This protective effect was primarily attributed to the attenuation of mitochondrial damage induced by IRI. Additionally, the authors noted an anti-inflammatory effect, in which H2S hindered leukocyte rolling and adhesion in postischemic intestine. The protective effect of H2S against intestinal IRI observed in this study demonstrates the possible utility of H2S pre-treatment in instances of predictable induction of intestinal IRI, such as intestinal transplantation.

5.5. H2S Pre-Treatment against Warm Pulmonary IRI

Pulmonary IRI is a complication of surgical procedures, such as lung transplantation and cardiopulmonary bypass surgery, as well as pulmonary embolism [78]. The effectiveness of H2S pre-treatment against pulmonary IRI was examined in a study by Jiang et al. [79]. The authors demonstrated that the administration of GYY4137 prior to the occlusion the lung hilum in diabetic rats attenuated warm pulmonary IRI by reducing apoptosis and inflammation. These effects were attributed to the activation of the SIRT-1 pathway, which promoted Nrf2/HO-1 and eNOS-mediated antioxidant signaling pathways. If hydrogen sulfide pre-treatment does indeed provide clinically significant protection against warm pulmonary IRI, the utility of this therapeutic would benefit lung transplant and cardiopulmonary bypass surgeries tremendously.

6. Sodium Thiosulfate: A Clinically Viable H2S Donor Drug against IRI

When considering the clinical relevance of H2S pre-treatment against IRI, the non-viability of gaseous H2S demonstrates the need for clinically viable donor molecules that can exhibit therapeutic potential against IRI. While the H2S donor molecules used in the studies above (GYY4137, AP39, and NaHS) demonstrated protective effects in animal models of IRI, clinical translation of these compounds is years away. Alternatively, STS is an H2S donor molecule that could expedite clinical translation as it is already used clinically for the treatment of acute cyanide poisoning, cisplatin toxicity in cancer patients, and calciphylaxis in patients with end-stage renal disease [83,84,85,86]. Thiosulfate is produced endogenously from H2S through the mitochondrial sulfide oxidation pathway, which we recently reviewed [87]. Importantly, the reverse reaction also occurs whereby H2S is generated from thiosulfate [87]. A small body of literature has examined the effects of STS in IRI. Marutani et al. [43] demonstrated that following warm cerebral IRI, a single dose or week-long regimen of intraperitoneal STS injections improved the survival rate and neurological function in mice. In addition, Sen et al. [88] found that STS provided cardioprotective effects when administered after generating an atrioventricular fistula. These effects were accompanied by an increase in endogenous H2S, which was suggested to be responsible for the therapeutic effects. Recently, a clinical trial in the Netherlands examined the effects of administering STS to patients presenting with ST-segment elevation myocardial infarction prior to restoring perfusion through percutaneous coronary intervention [89]. Unfortunately, the researchers observed no effect of the STS treatment on infarct size, leading to the discontinuation of the trial [90]. However, Ravindran et al. [80] demonstrated that STS pre-treatment is protective against cell death, ROS accumulation, and mitochondrial dysfunction induced by in vitro hypoxia and re-oxygenation in cardiomyocytes. By occluding the left anterior descending artery, these researchers also observed similar protective effects of STS pre-treatment in an ex vivo model of warm IRI in rat hearts. The authors further reported that STS pre-treatment preserved mitochondrial integrity, leading to protection against warm myocardial IRI [81]. However, such protection conferred by STS was abolished in the presence of PI3K/mTOR/KATP inhibitors [82], suggesting that the mechanism underlying STS protection against myocardial IRI is at least partially via the PI3K/mTOR/KATP pathway.

7. Ethics and Regulations

The concept of treating an organ donor prior to graft procurement may raise several ethical issues. In the context of H2S donor pre-treatment, a major ethical issue would be the possible toxicity of H2S [39,40]. Such an ethical issue would be particularly problematic in the context of living donors, where the administration of H2S donor molecules could cause serious side effects in the organ donor. It must be emphasized that treatment of living donors with any class of drugs for the purpose of ameliorating transplantation outcomes in the recipient must not harm the donor in any way. Accordingly, extensive pre-clinical and clinical studies would need to be conducted to identify a safe and efficacious dose of a clinically viable H2S donor for administration in humans. The optimal dosage would depend on the specific H2S donor used since different H2S donors have different potencies [52]. A potential approach to facilitate the translation of H2S donor pre-treatment from bench to bedside would be to focus on H2S donors that are already approved by national health regulatory agencies, such as STS [91,92]. However, it is important to note that STS treatment is associated with adverse side effects, such as hypotension, headaches, nausea, and vomiting [91]. To confer protection against IRI, the required dose of STS may be higher than the recommended dose [91], which could lead to worsened side effects in the organ donor. Nonetheless, research focused on protection against IRI should prioritize the use of H2S donors clinically approved for other diseases, since such H2S donor drugs would be more likely to receive approval for use in transplantation. Another important factor to consider is that treating a living organ donor with a drug before procurement of the organ graft may dissuade the donor from donating the organ. The decision to donate an organ and the pre-transplantation phase can cause great psychological stress in a prospective donor [93,94,95,96]. Compounding the stress of donating an organ with receiving treatment that would likely not benefit the donor but could cause harm may discourage an organ donor from deciding to donate. For example, Pillay et al. [94] reported that stem cell donors experienced anxiety toward the possible adverse effects of being pre-treated with granulocyte-stimulating factor, which is administered to bone marrow donors before and during transplantation [97]. If H2S donor pre-treatment of living organ donors is to have clinical relevance, research should be conducted to assess the impact of H2S donor pre-treatment on an individual’s decision to donate an organ.
Shifting the focus to pre-treating deceased donors, current international approaches to consent for organ donation require donative intent, which is distinct from informed consent [98]. Donative intent is simply the requirement that an individual formally indicates their intention to donate an organ [98]. The organ donor can choose to be informed and decide to donate their organ(s) without the involvement of a healthcare team [98]. If an individual formally declares their intention to donate, then treatment of the deceased donor with a drug would not require informed consent if such an organ procurement protocol is clinically approved. However, an important consideration that must be made with respect to donation from deceased donors is the clinical relevance of pre-treating such donors. In the case of donation after brain death (DBD), such donors are declared dead based on neurologic criteria; the circulatory system in these patients remains functional [99,100]. Thus, drugs, such as H2S, administered to these organ donors should effectively circulate in the body. By contrast, circulatory function in DCD donors is compromised [99,100], which may impair the ability of a pre-treatment agent to act on its target organ, depending on the organ of interest. As reported in the study by Meng et al. [56], H2S pre-treatment of DCD donors in lung transplantation is feasible since the lungs can simply be inflated with gaseous H2S. However, H2S donor pre-treatment of DCD donors may be more challenging in the context of other organs. It is important to note that there are two major types of DCDs: uncontrolled and controlled [99,100,101]. In the context of controlled DCDs, the cessation of circulation is anticipated [99,100,101] and thus in this scenario, administration of a pre-treatment agent prior to the onset of ischemia should be possible. By contrast, pre-treatment of uncontrolled DCD donors prior to the onset of ischemia would be unattainable since there would be no prior anticipation of the circulatory cessation [99,100,101], at which point warm ischemia would take place. Despite the inability to administer treatment prior to warm ischemia, it would still be possible to administer treatment to DCD donors before the induction of cold ischemia. A major challenge would be circulating the pre-treatment agent to the organ of interest due to the lack of circulation. However, cardiovascular resuscitation (CPR) may serve as a potential option for circulating pre-treatment agents in DCD donors prior to organ harvesting and cold ischemic induction. For instance, Limkemann et al. [102] found that intravenous administration of gluconate, a cell impermeant, combined with CPR following circulatory death in rats reduced cell swelling and death along with liver injury in an ex vivo model of cold hepatic IRI. Interestingly, the authors showed that CPR distributed gluconate to various tissues in the body in a similar fashion to cardiac circulation. Although this research was conducted using gluconate as a pre-treatment agent, CPR could potentially help circulate H2S donor molecules in DCD donors. If any drug is to be used for pre-treating DCD donors to enhance transplantation success, the ability to circulate the drug of interest in the donor should be investigated to ensure the effectiveness of the treatment.
Collectively, pre-treating organ donors to protect against IRI and thereby enhance transplantation outcomes in recipients presents several ethical questions that must be considered. The importance of addressing these ethical and regulatory questions should be emphasized, as the concept of organ donor pre-treatment is becoming more of a clinical possibility. As previously mentioned, a clinical trial focused on pre-treating neurologically deceased kidney donors with tacrolimus to protect against renal IRI and improve post-transplantation outcomes is currently underway in Canada [13]. Importantly, this trial is funded by the Canadian Institutes of Health Research (CIHR) and has received approval from both federal and provincial health regulatory agencies [103]. The trial, referred to as the CINERGY pilot trial, may pave the way for future clinical trials focused on organ donor pre-treatment.

8. Conclusions

In conclusion, the alternative approach of pre-treating transplant donors with H2S donor compounds may enhance post-transplantation outcomes in recipients by protecting against IRI. The lack of literature surrounding H2S pre-treatment in the context of transplantation demonstrates a key research area with great potential. Considering that many studies have shown that H2S pre-treatment is protective against warm IRI, it is likely that H2S pre-treatment can protect against transplantation-induced cold IRI. Importantly, research in this area could enhance transplantation success and thereby improve the survival and quality of life of transplant recipients. As such, our research group is currently examining whether STS pre-treatment of donors can protect against transplantation-induced renal IRI. If a protective effect is established, the ethical implications of donor pre-treatment will need to be considered for clinical translation. Indeed, donor pre-treatment is becoming more of a clinical possibility, as evidenced by the CINERGY pilot trial, and may ultimately represent the future of transplantation.

Author Contributions

Conceptualization: A.S. and G.J.D.; Manuscript writing: L.M. and P.N.; Review and editing: G.J.D. and A.S.; Figures: L.M. and P.N.; Supervision: G.J.D. and A.S.; Approval: A.S. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by Lawson Internal Research Fund and Department of Surgery Research Fund at Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interests.

References

  1. Dugbartey, G.J.; Juriasingani, S.; Zhang, M.Y.; Sener, A. H2S Donor Molecules against Cold Ischemia-Reperfusion Injury in Preclinical Models of Solid Organ Transplantation. Pharmacol. Res. 2021, 172, 105842. [Google Scholar] [CrossRef] [PubMed]
  2. Hosgood, S.A.; Brown, R.J.; Nicholson, M.L. Advances in Kidney Preservation Techniques and Their Application in Clinical Practice. Transplantation 2021, 105, e202–e214. [Google Scholar] [CrossRef] [PubMed]
  3. Jamieson, R.W.; Friend, P.J. Organ Reperfusion and Preservation. Front. Biosci. 2008, 13, 221–235. [Google Scholar] [CrossRef] [PubMed]
  4. Salvadori, M.; Rosso, G.; Bertoni, E. Update on Ischemia-Reperfusion Injury in Kidney Transplantation: Pathogenesis and Treatment. World J. Transplant. 2015, 5, 52–67. [Google Scholar] [CrossRef]
  5. Zhao, H.; Alam, A.; Soo, A.P.; George, A.J.T.; Ma, D. Ischemia-Reperfusion Injury Reduces Long Term Renal Graft Survival: Mechanism and Beyond. EBioMedicine 2018, 28, 31–42. [Google Scholar] [CrossRef]
  6. Sibulesky, L.; Li, M.; Hansen, R.N.; Dick, A.A.S.; Montenovo, M.I.; Rayhill, S.C.; Bakthavatsalam, R.; Reyes, J.D. Impact of Cold Ischemia Time on Outcomes of Liver Transplantation: A Single Center Experience. Ann. Transplant. 2016, 21, 145–151. [Google Scholar] [CrossRef]
  7. Ward, A.; Klassen, D.K.; Franz, K.M.; Giwa, S.; Lewis, J.K. Social, Economic, and Policy Implications of Organ Preservation Advances. Curr. Opin. Organ Transplant. 2018, 23, 336–346. [Google Scholar] [CrossRef]
  8. Sanada, S.; Komuro, I.; Kitakaze, M. Pathophysiology of Myocardial Reperfusion Injury: Preconditioning, Postconditioning, and Translational Aspects of Protective Measures. Am. J. Physiol. -Heart Circ. Physiol. 2011, 301, H1723–H1741. [Google Scholar] [CrossRef]
  9. Sponga, S.; Benedetti, G.; de Manna, N.D.; Ferrara, V.; Vendramin, I.; Lechiancole, A.; Maiani, M.; Nalon, S.; Nalli, C.; Di Nora, C.; et al. Heart Transplant Outcomes in Patients with Mechanical Circulatory Support: Cold Storage versus Normothermic Perfusion Organ Preservation. Interact. Cardiovasc. Thorac. Surg. 2021, 32, 476–482. [Google Scholar] [CrossRef]
  10. van Beekum, C.J.; Vilz, T.O.; Glowka, T.R.; von Websky, M.W.; Kalff, J.C.; Manekeller, S. Normothermic Machine Perfusion (NMP) of the Liver—Current Status and Future Perspectives. Ann. Transplant. 2021, 26, e931664. [Google Scholar] [CrossRef]
  11. Patel, S.V.B.; Sener, A.; Bhattacharjee, R.N.; Luke, P.P.W. Machine Preservation of Donor Kidneys in Transplantation. Transl. Androl. Urol. 2019, 8, 118–125. [Google Scholar] [CrossRef]
  12. Niemann, C.U.; Feiner, J.; Swain, S.; Bunting, S.; Friedman, M.; Crutchfield, M.; Broglio, K.; Hirose, R.; Roberts, J.P.; Malinoski, D. Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function. N. Engl. J. Med. 2015, 373, 405–414. [Google Scholar] [CrossRef]
  13. Université de Sherbrooke. Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney DelaYed Graft Function (CINERGY)-Pilot Trial. 2021. Available online: clinicaltrials.gov (accessed on 4 December 2022).
  14. Juriasingani, S.; Ruthirakanthan, A.; Richard-Mohamed, M.; Akbari, M.; Aquil, S.; Patel, S.; Al-Ogaili, R.; Whiteman, M.; Luke, P.; Sener, A. Subnormothermic Perfusion with H2S Donor AP39 Improves DCD Porcine Renal Graft Outcomes in an Ex Vivo Model of Kidney Preservation and Reperfusion. Biomolecules 2021, 11, 446. [Google Scholar] [CrossRef]
  15. Zhang, M.Y.; Dugbartey, G.J.; Juriasingani, S.; Akbari, M.; Liu, W.; Haig, A.; McLeod, P.; Arp, J.; Sener, A. Sodium Thiosulfate-Supplemented UW Solution Protects Renal Grafts against Prolonged Cold Ischemia-Reperfusion Injury in a Murine Model of Syngeneic Kidney Transplantation. Biomed. Pharmacother. 2022, 145, 112435. [Google Scholar] [CrossRef]
  16. Zhang, H.; Yan, Q.; Wang, X.; Chen, X.; Chen, Y.; Du, J.; Chen, L. The Role of Mitochondria in Liver Ischemia-Reperfusion Injury: From Aspects of Mitochondrial Oxidative Stress, Mitochondrial Fission, Mitochondrial Membrane Permeable Transport Pore Formation, Mitophagy, and Mitochondria-Related Protective Measures. Oxid. Med. Cell Longev. 2021, 2021, 6670579. [Google Scholar] [CrossRef]
  17. Granger, D.N.; Kvietys, P.R. Reperfusion Injury and Reactive Oxygen Species: The Evolution of a Concept. Redox Biol. 2015, 6, 524–551. [Google Scholar] [CrossRef]
  18. Kalogeris, T.; Baines, C.P.; Krenz, M.; Korthuis, R.J. Cell Biology of Ischemia/Reperfusion Injury. Int. Rev. Cell Mol. Biol. 2012, 298, 229–317. [Google Scholar] [CrossRef]
  19. Kalogeris, T.; Baines, C.P.; Krenz, M.; Korthuis, R.J. Ischemia/Reperfusion. Compr. Physiol. 2016, 7, 113–170. [Google Scholar] [CrossRef]
  20. Rouslin, W. Mitochondrial Complexes I, II, III, IV, and V in Myocardial Ischemia and Autolysis. Am. J. Physiol. -Heart Circ. Physiol. 1983, 244, H743–H748. [Google Scholar] [CrossRef]
  21. Jassem, W.; Roake, J. The Molecular and Cellular Basis of Reperfusion Injury Following Organ Transplantation. Transplant. Rev. 1998, 12, 14–33. [Google Scholar] [CrossRef]
  22. Lubos, E.; Loscalzo, J.; Handy, D.E. Glutathione Peroxidase-1 in Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities. Antioxid. Redox Signal. 2011, 15, 1957–1997. [Google Scholar] [CrossRef] [PubMed]
  23. Chouchani, E.T.; Pell, V.R.; Gaude, E.; Aksentijević, D.; Sundier, S.Y.; Robb, E.L.; Logan, A.; Nadtochiy, S.M.; Ord, E.N.J.; Smith, A.C.; et al. Ischaemic Accumulation of Succinate Controls Reperfusion Injury through Mitochondrial ROS. Nature 2014, 515, 431–435. [Google Scholar] [CrossRef] [PubMed]
  24. Arduini, A.; Mezzetti, A.; Porreca, E.; Lapenna, D.; DeJulia, J.; Marzio, L.; Polidoro, G.; Cuccurullo, F. Effect of Ischemia and Reperfusion on Antioxidant Enzymes and Mitochondrial Inner Membrane Proteins in Perfused Rat Heart. Biochim. Et Biophys. Acta (BBA)—Mol. Cell Res. 1988, 970, 113–121. [Google Scholar] [CrossRef]
  25. Neri, M.; Riezzo, I.; Pascale, N.; Pomara, C.; Turillazzi, E. Ischemia/Reperfusion Injury Following Acute Myocardial Infarction: A Critical Issue for Clinicians and Forensic Pathologists. Mediat. Inflamm. 2017, 2017, 7018393. [Google Scholar] [CrossRef] [PubMed]
  26. Tonnus, W.; Linkermann, A. The in Vivo Evidence for Regulated Necrosis. Immunol. Rev. 2017, 277, 128–149. [Google Scholar] [CrossRef]
  27. Belavgeni, A.; Meyer, C.; Stumpf, J.; Hugo, C.; Linkermann, A. Ferroptosis and Necroptosis in the Kidney. Cell Chem. Biol. 2020, 27, 448–462. [Google Scholar] [CrossRef]
  28. Jiang, M.; Liu, K.; Luo, J.; Dong, Z. Autophagy Is a Renoprotective Mechanism During in Vitro Hypoxia and in Vivo Ischemia-Reperfusion Injury. Am. J. Pathol. 2010, 176, 1181–1192. [Google Scholar] [CrossRef]
  29. Stockwell, B.R.; Friedmann Angeli, J.P.; Bayir, H.; Bush, A.I.; Conrad, M.; Dixon, S.J.; Fulda, S.; Gascón, S.; Hatzios, S.K.; Kagan, V.E.; et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 2017, 171, 273–285. [Google Scholar] [CrossRef]
  30. Eltzschig, H.K.; Eckle, T. Ischemia and Reperfusion—From Mechanism to Translation. Nat. Med. 2011, 17, 1391–1401. [Google Scholar] [CrossRef]
  31. Dorweiler, B.; Pruefer, D.; Andrasi, T.B.; Maksan, S.M.; Schmiedt, W.; Neufang, A.; Vahl, C.F. Ischemia-Reperfusion Injury: Pathophysiology and Clinical Implications. Eur. J. Trauma Emerg. Surg. 2007, 33, 600–612. [Google Scholar] [CrossRef]
  32. Arumugam, T.V.; Shiels, I.A.; Woodruff, T.M.; Granger, D.N.; Taylor, S.M. The role of the complement system in ischemia-reperfusion injury. Shock 2004, 21, 401–409. [Google Scholar] [CrossRef]
  33. Dugbartey, G.J. Carbon monoxide as an emerging pharmacological tool to improve lung and liver transplantation protocols. Biochem. Pharmacol. 2021, 193, 114752. [Google Scholar] [CrossRef]
  34. Chen, X.; Jhee, K.-H.; Kruger, W.D. Production of the Neuromodulator H2S by Cystathionine Beta-Synthase via the Condensation of Cysteine and Homocysteine. J. Biol. Chem. 2004, 279, 52082–52086. [Google Scholar] [CrossRef]
  35. Majtan, T.; Krijt, J.; Sokolová, J.; Křížková, M.; Ralat, M.A.; Kent, J.; Gregory, J.F.; Kožich, V.; Kraus, J.P. Biogenesis of Hydrogen Sulfide and Thioethers by Cystathionine Beta-Synthase. Antioxid. Redox Signal. 2018, 28, 311–323. [Google Scholar] [CrossRef]
  36. Chiku, T.; Padovani, D.; Zhu, W.; Singh, S.; Vitvitsky, V.; Banerjee, R. H2S Biogenesis by Human Cystathionine Gamma-Lyase Leads to the Novel Sulfur Metabolites Lanthionine and Homolanthionine and Is Responsive to the Grade of Hyperhomocysteinemia. J. Biol. Chem. 2009, 284, 11601–11612. [Google Scholar] [CrossRef]
  37. Shibuya, N.; Koike, S.; Tanaka, M.; Ishigami-Yuasa, M.; Kimura, Y.; Ogasawara, Y.; Fukui, K.; Nagahara, N.; Kimura, H. A Novel Pathway for the Production of Hydrogen Sulfide from D-Cysteine in Mammalian Cells. Nat. Commun. 2013, 4, 1366. [Google Scholar] [CrossRef]
  38. Shibuya, N.; Tanaka, M.; Yoshida, M.; Ogasawara, Y.; Togawa, T.; Ishii, K.; Kimura, H. 3-Mercaptopyruvate Sulfurtransferase Produces Hydrogen Sulfide and Bound Sulfane Sulfur in the Brain. Antioxid. Redox Signal. 2009, 11, 703–714. [Google Scholar] [CrossRef]
  39. Szabo, C.; Papapetropoulos, A. International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors. Pharmacol. Rev. 2017, 69, 497–564. [Google Scholar] [CrossRef]
  40. Jiang, J.; Chan, A.; Ali, S.; Saha, A.; Haushalter, K.J.; Lam, W.-L.M.; Glasheen, M.; Parker, J.; Brenner, M.; Mahon, S.B.; et al. Hydrogen Sulfide--Mechanisms of Toxicity and Development of an Antidote. Sci. Rep. 2016, 6, 20831. [Google Scholar] [CrossRef]
  41. Blackstone, E.; Morrison, M.; Roth, M.B. H2S Induces a Suspended Animation-like State in Mice. Science 2005, 308, 518. [Google Scholar] [CrossRef]
  42. Dugbartey, G.J.; Talaei, F.; Houwertjes, M.C.; Goris, M.; Epema, A.H.; Bouma, H.R.; Henning, R.H. Dopamine Treatment Attenuates Acute Kidney Injury in a Rat Model of Deep Hypothermia and Rewarming—The Role of Renal H2S-Producing Enzymes. Eur. J. Pharmacol. 2015, 769, 225–233. [Google Scholar] [CrossRef] [PubMed]
  43. Marutani, E.; Yamada, M.; Ida, T.; Tokuda, K.; Ikeda, K.; Kai, S.; Shirozu, K.; Hayashida, K.; Kosugi, S.; Hanaoka, K.; et al. Thiosulfate Mediates Cytoprotective Effects of Hydrogen Sulfide Against Neuronal Ischemia. J. Am. Heart Assoc. 2015, 4, e002125. [Google Scholar] [CrossRef] [PubMed]
  44. Jha, S.; Calvert, J.W.; Duranski, M.R.; Ramachandran, A.; Lefer, D.J. Hydrogen Sulfide Attenuates Hepatic Ischemia-Reperfusion Injury: Role of Antioxidant and Antiapoptotic Signaling. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, H801–H806. [Google Scholar] [CrossRef] [PubMed]
  45. Jensen, A.R.; Drucker, N.A.; Khaneki, S.; Ferkowicz, M.J.; Markel, T.A. Hydrogen Sulfide Improves Intestinal Recovery Following Ischemia by Endothelial Nitric Oxide-Dependent Mechanisms. Am. J. Physiol. Gastrointest. Liver Physiol. 2017, 312, G450–G456. [Google Scholar] [CrossRef]
  46. Elrod, J.W.; Calvert, J.W.; Morrison, J.; Doeller, J.E.; Kraus, D.W.; Tao, L.; Jiao, X.; Scalia, R.; Kiss, L.; Szabo, C.; et al. Hydrogen Sulfide Attenuates Myocardial Ischemia-Reperfusion Injury by Preservation of Mitochondrial Function. Proc. Natl. Acad. Sci. USA 2007, 104, 15560–15565. [Google Scholar] [CrossRef]
  47. Nishime, K.; Miyagi-Shiohira, C.; Kuwae, K.; Tamaki, Y.; Yonaha, T.; Sakai-Yonaha, M.; Saitoh, I.; Watanabe, M.; Noguchi, H. Preservation of Pancreas in the University of Wisconsin Solution Supplemented with AP39 Reduces Reactive Oxygen Species Production and Improves Islet Graft Function. Am. J. Transplant. 2021, 21, 2698–2708. [Google Scholar] [CrossRef]
  48. George, T.J.; Arnaoutakis, G.J.; Beaty, C.A.; Jandu, S.K.; Santhanam, L.; Berkowitz, D.E.; Shah, A.S. Hydrogen Sulfide Decreases Reactive Oxygen in a Model of Lung Transplantation. J. Surg. Res. 2012, 178, 494–501. [Google Scholar] [CrossRef]
  49. Lobb, I.; Mok, A.; Lan, Z.; Liu, W.; Garcia, B.; Sener, A. Supplemental Hydrogen Sulphide Protects Transplant Kidney Function and Prolongs Recipient Survival after Prolonged Cold Ischaemia-Reperfusion Injury by Mitigating Renal Graft Apoptosis and Inflammation. BJU Int. 2012, 110, E1187–E1195. [Google Scholar] [CrossRef]
  50. Han, S.J.; Kim, J.I.; Park, J.-W.; Park, K.M. Hydrogen Sulfide Accelerates the Recovery of Kidney Tubules after Renal Ischemia/Reperfusion Injury. Nephrol. Dial. Transplant. 2015, 30, 1497–1506. [Google Scholar] [CrossRef]
  51. Ahmad, A.; Olah, G.; Szczesny, B.; Wood, M.E.; Whiteman, M.; Szabo, C. AP39, A Mitochondrially Targeted Hydrogen Sulfide Donor, Exerts Protective Effects in Renal Epithelial Cells Subjected to Oxidative Stress in Vitro and in Acute Renal Injury in Vivo. Shock 2016, 45, 88–97. [Google Scholar] [CrossRef]
  52. Lobb, I.; Jiang, J.; Lian, D.; Liu, W.; Haig, A.; Saha, M.N.; Torregrossa, R.; Wood, M.E.; Whiteman, M.; Sener, A. Hydrogen Sulfide Protects Renal Grafts Against Prolonged Cold Ischemia-Reperfusion Injury via Specific Mitochondrial Actions. Am. J. Transplant. 2017, 17, 341–352. [Google Scholar] [CrossRef]
  53. George, T.J.; Arnaoutakis, G.J.; Beaty, C.A.; Jandu, S.K.; Santhanam, L.; Berkowitz, D.E.; Shah, A.S. Inhaled Hydrogen Sulfide Improves Graft Function in an Experimental Model of Lung Transplantation. J. Surg. Res. 2012, 178, 593–600. [Google Scholar] [CrossRef]
  54. Goubern, M.; Andriamihaja, M.; Nübel, T.; Blachier, F.; Bouillaud, F. Sulfide, the First Inorganic Substrate for Human Cells. FASEB J. 2007, 21, 1699–1706. [Google Scholar] [CrossRef]
  55. Kroemer, G.; Reed, J.C. Mitochondrial Control of Cell Death. Nat. Med. 2000, 6, 513–519. [Google Scholar] [CrossRef]
  56. Meng, C.; Cui, X.; Qi, S.; Zhang, J.; Kang, J.; Zhou, H. Lung Inflation with Hydrogen Sulfide during the Warm Ischemia Phase Ameliorates Injury in Rat Donor Lungs via Metabolic Inhibition after Cardiac Death. Surgery 2017, 161, 1287–1298. [Google Scholar] [CrossRef]
  57. Hayden, M.S.; West, A.P.; Ghosh, S. NF-KappaB and the Immune Response. Oncogene 2006, 25, 6758–6780. [Google Scholar] [CrossRef]
  58. Yamamoto, M.; Kensler, T.W.; Motohashi, H. The KEAP1-NRF2 System: A Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. Physiol. Rev. 2018, 98, 1169–1203. [Google Scholar] [CrossRef]
  59. Bos, E.M.; Wang, R.; Snijder, P.M.; Boersema, M.; Damman, J.; Fu, M.; Moser, J.; Hillebrands, J.-L.; Ploeg, R.J.; Yang, G.; et al. Cystathionine γ-Lyase Protects against Renal Ischemia/Reperfusion by Modulating Oxidative Stress. J. Am. Soc. Nephrol. 2013, 24, 759–770. [Google Scholar] [CrossRef]
  60. Hesketh, E.E.; Czopek, A.; Clay, M.; Borthwick, G.; Ferenbach, D.; Kluth, D.; Hughes, J. Renal Ischaemia Reperfusion Injury: A Mouse Model of Injury and Regeneration. J. Vis. Exp. 2014, 88, 51816. [Google Scholar] [CrossRef]
  61. Bos, E.M.; Leuvenink, H.G.D.; Snijder, P.M.; Kloosterhuis, N.J.; Hillebrands, J.-L.; Leemans, J.C.; Florquin, S.; van Goor, H. Hydrogen Sulfide-Induced Hypometabolism Prevents Renal Ischemia/Reperfusion Injury. J. Am. Soc. Nephrol. 2009, 20, 1901–1905. [Google Scholar] [CrossRef]
  62. Azizi, F.; Seifi, B.; Kadkhodaee, M.; Ahghari, P. Administration of Hydrogen Sulfide Protects Ischemia Reperfusion-Induced Acute Kidney Injury by Reducing the Oxidative Stress. Ir. J. Med. Sci. 2016, 185, 649–654. [Google Scholar] [CrossRef] [PubMed]
  63. Hashmi, S.F.; Rathore, H.A.; Sattar, M.A.; Johns, E.J.; Gan, C.-Y.; Chia, T.Y.; Ahmad, A. Hydrogen Sulphide Treatment Prevents Renal Ischemia-Reperfusion Injury by Inhibiting the Expression of ICAM-1 and NF-KB Concentration in Normotensive and Hypertensive Rats. Biomolecules 2021, 11, 1549. [Google Scholar] [CrossRef] [PubMed]
  64. Zhao, H.; Qiu, Y.; Wu, Y.; Sun, H.; Gao, S. Protective Effects of GYY4137 on Renal Ischaemia/Reperfusion Injury through Nrf2-Mediated Antioxidant Defence. Kidney Blood Press Res. 2021, 46, 257–265. [Google Scholar] [CrossRef] [PubMed]
  65. Kellum, J.A.; Romagnani, P.; Ashuntantang, G.; Ronco, C.; Zarbock, A.; Anders, H.-J. Acute Kidney Injury. Nat. Rev. Dis. Prim. 2021, 7, 52. [Google Scholar] [CrossRef]
  66. Morcos, R.; Kucharik, M.; Bansal, P.; Al Taii, H.; Manam, R.; Casale, J.; Khalili, H.; Maini, B. Contrast-Induced Acute Kidney Injury: Review and Practical Update. Clin. Med. Insights Cardiol. 2019, 13, 1179546819878680. [Google Scholar] [CrossRef]
  67. Araszkiewicz, A.; Grygier, M.; Lesiak, M.; Grajek, S. The Impact of Ischemia-Reperfusion Injury on the Effectiveness of Primary Angioplasty in ST-Segment Elevation Myocardial Infarction. Postep. Kardiol. Interwencyjnej 2013, 9, 275–281. [Google Scholar] [CrossRef]
  68. Sivarajah, A.; Collino, M.; Yasin, M.; Benetti, E.; Gallicchio, M.; Mazzon, E.; Cuzzocrea, S.; Fantozzi, R.; Thiemermann, C. Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock 2009, 31, 267–274. [Google Scholar] [CrossRef]
  69. Pan, T.-T.; Chen, Y.Q.; Bian, J.-S. All in the Timing: A Comparison between the Cardioprotection Induced by H2S Preconditioning and Post-Infarction Treatment. Eur. J. Pharmacol. 2009, 616, 160–165. [Google Scholar] [CrossRef]
  70. Leon, B.M.; Maddox, T.M. Diabetes and Cardiovascular Disease: Epidemiology, Biological Mechanisms, Treatment Recommendations and Future Research. World J. Diabetes 2015, 6, 1246–1258. [Google Scholar] [CrossRef]
  71. Peake, B.F.; Nicholson, C.K.; Lambert, J.P.; Hood, R.L.; Amin, H.; Amin, S.; Calvert, J.W. Hydrogen Sulfide Preconditions the Db/Db Diabetic Mouse Heart against Ischemia-Reperfusion Injury by Activating Nrf2 Signaling in an Erk-Dependent Manner. Am. J. Physiol. Heart Circ. Physiol. 2013, 304, H1215–H1224. [Google Scholar] [CrossRef]
  72. Cannistrà, M.; Ruggiero, M.; Zullo, A.; Gallelli, G.; Serafini, S.; Maria, M.; Naso, A.; Grande, R.; Serra, R.; Nardo, B. Hepatic Ischemia Reperfusion Injury: A Systematic Review of Literature and the Role of Current Drugs and Biomarkers. Int. J. Surg. 2016, 33, S57–S70. [Google Scholar] [CrossRef]
  73. Zhang, Q.; Fu, H.; Zhang, H.; Xu, F.; Zou, Z.; Liu, M.; Wang, Q.; Miao, M.; Shi, X. Hydrogen Sulfide Preconditioning Protects Rat Liver against Ischemia/Reperfusion Injury by Activating Akt-GSK-3β Signaling and Inhibiting Mitochondrial Permeability Transition. PLoS ONE 2013, 8, e74422. [Google Scholar] [CrossRef]
  74. Cheng, P.; Wang, F.; Chen, K.; Shen, M.; Dai, W.; Xu, L.; Zhang, Y.; Wang, C.; Li, J.; Yang, J.; et al. Hydrogen Sulfide Ameliorates Ischemia/Reperfusion-Induced Hepatitis by Inhibiting Apoptosis and Autophagy Pathways. Mediat. Inflamm. 2014, 2014, 935251. [Google Scholar] [CrossRef]
  75. Pierro, A.; Eaton, S. Intestinal Ischemia Reperfusion Injury and Multisystem Organ Failure. Semin. Pediatr. Surg. 2004, 13, 11–17. [Google Scholar] [CrossRef]
  76. Liu, H.; Bai, X.-B.; Shi, S.; Cao, Y.-X. Hydrogen Sulfide Protects from Intestinal Ischaemia–Reperfusion Injury in Rats. J. Pharm. Pharmacol. 2009, 61, 207–212. [Google Scholar] [CrossRef]
  77. Liu, Y.; Kalogeris, T.; Wang, M.; Zuidema, M.Y.; Wang, Q.; Dai, H.; Davis, M.J.; Hill, M.A.; Korthuis, R.J. Hydrogen Sulfide Preconditioning or Neutrophil Depletion Attenuates Ischemia-Reperfusion-Induced Mitochondrial Dysfunction in Rat Small Intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302, G44–G54. [Google Scholar] [CrossRef]
  78. Ferrari, R.S.; Andrade, C.F. Oxidative Stress and Lung Ischemia-Reperfusion Injury. Oxidative Med. Cell. Longev. 2015, 2015, e590987. [Google Scholar] [CrossRef]
  79. Jiang, T.; Yang, W.; Zhang, H.; Song, Z.; Liu, T.; Lv, X. Hydrogen Sulfide Ameliorates Lung Ischemia-Reperfusion Injury Through SIRT1 Signaling Pathway in Type 2 Diabetic Rats. Front. Physiol. 2020, 11, 596. [Google Scholar] [CrossRef]
  80. Ravindran, S.; Boovarahan, S.R.; Shanmugam, K.; Vedarathinam, R.C.; Kurian, G.A. Sodium Thiosulfate Preconditioning Ameliorates Ischemia/Reperfusion Injury in Rat Hearts Via Reduction of Oxidative Stress and Apoptosis. Cardiovasc. Drugs Ther. 2017, 31, 511–524. [Google Scholar] [CrossRef]
  81. Ravindran, S.; Kurian, G.A. Preconditioning the Rat Heart with Sodium Thiosulfate Preserved the Mitochondria in Response to Ischemia-Reperfusion Injury. J. Bioenergy Biomembr. 2019, 51, 189–201. [Google Scholar] [CrossRef]
  82. Boovarahan, S.R.; Venkatasubramanian, H.; Sharma, N.; Venkatesh, S.; Prem, P.; Kurian, G.A. Inhibition of PI3K/MTOR/KATP Channel Blunts Sodium Thiosulphate Preconditioning Mediated Cardioprotection against Ischemia–Reperfusion Injury. Arch. Pharm. Res. 2021, 44, 605–620. [Google Scholar] [CrossRef]
  83. Bebarta, V.S.; Brittain, M.; Chan, A.; Garrett, N.; Yoon, D.; Burney, T.; Mukai, D.; Babin, M.; Pilz, R.B.; Mahon, S.B.; et al. Sodium Nitrite and Sodium Thiosulfate Are Effective Against Acute Cyanide Poisoning When Administered by Intramuscular Injection. Ann. Emerg. Med. 2017, 69, 718–725.e4. [Google Scholar] [CrossRef] [PubMed]
  84. Tsang, R.Y.; Al-Fayea, T.; Au, H.-J. Cisplatin Overdose. Drug-Safety 2009, 32, 1109–1122. [Google Scholar] [CrossRef] [PubMed]
  85. Strazzula, L.; Nigwekar, S.U.; Steele, D.; Tsiaras, W.; Sise, M.; Bis, S.; Smith, G.P.; Kroshinsky, D. Intralesional Sodium Thiosulfate for the Treatment of Calciphylaxis. JAMA Dermatol. 2013, 149, 946–949. [Google Scholar] [CrossRef] [PubMed]
  86. Peng, T.; Zhuo, L.; Wang, Y.; Jun, M.; Li, G.; Wang, L.; Hong, D. Systematic Review of Sodium Thiosulfate in Treating Calciphylaxis in Chronic Kidney Disease Patients. Nephrology 2018, 23, 669–675. [Google Scholar] [CrossRef]
  87. Zhang, M.Y.; Dugbartey, G.J.; Juriasingani, S.; Sener, A. Hydrogen Sulfide Metabolite, Sodium Thiosulfate: Clinical Applications and Underlying Molecular Mechanisms. Int. J. Mol. Sci. 2021, 22, 6452. [Google Scholar] [CrossRef]
  88. Sen, U.; Vacek, T.P.; Hughes, W.M.; Kumar, M.; Moshal, K.S.; Tyagi, N.; Metreveli, N.; Hayden, M.R.; Tyagi, S.C. Cardioprotective Role of Sodium Thiosulfate on Chronic Heart Failure by Modulating Endogenous H2S Generation. PHA 2008, 82, 201–213. [Google Scholar] [CrossRef]
  89. de Koning, M.-S.L.; van Dorp, P.; Assa, S.; Hartman, M.H.; Voskuil, M.; Anthonio, R.L.; Veen, D.; Pundziute-Do Prado, G.; Leiner, T.; van Goor, H.; et al. Rationale and Design of the Groningen Intervention Study for the Preservation of Cardiac Function with Sodium Thiosulfate after St-Segment Elevation Myocardial Infarction (GIPS-IV) Trial. Am. Heart J. 2022, 243, 167–176. [Google Scholar] [CrossRef]
  90. GIPS-IV: Sodium Thiosulfate Does Not Reduce Heart Damage After MI. Available online: https://www.acc.org/Latest-in-Cardiology/Articles/2022/04/03/13/22/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fArticles%2f2022%2f04%2f03%2f13%2f22%2fMon-11am-GIPS-IV-acc-2022 (accessed on 4 December 2022).
  91. Health Canada Seacalphyx. Available online: https://health-products.canada.ca/dpd-bdpp/info.do?code=87223&lang=en#fn1 (accessed on 19 November 2022).
  92. U.S. Food and Drug Administration Sodium Thiosulfate Injection, 250 mg/mL. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203923_sodium_thiosulfate_toc.cfm (accessed on 12 December 2022).
  93. Franklin, P.M.; Crombie, A.K. Live Related Renal Transplantation: Psychological, Social, and Cultural Issues. Transplantation 2003, 76, 1247–1252. [Google Scholar] [CrossRef]
  94. Pillay, B.; Lee, S.J.; Katona, L.; De Bono, S.; Warren, N.; Fletcher, J.; Burney, S. The Psychosocial Impact of Haematopoietic SCT on Sibling Donors. Bone Marrow Transplant. 2012, 47, 1361–1365. [Google Scholar] [CrossRef]
  95. Munzenberger, N.; Fortanier, C.; Macquart-Moulin, G.; Faucher, C.; Novakovitch, G.; Maraninchi, D.; Moatti, J.P.; Blaise, D. Psychosocial Aspects of Haematopoietic Stem Cell Donation for Allogeneic Transplantation: How Family Donors Cope with This Experience. Psychooncology 1999, 8, 55–63. [Google Scholar] [CrossRef]
  96. Clarke, A.; Mitchell, A.; Abraham, C. Understanding Donation Experiences of Unspecified (Altruistic) Kidney Donors. Br. J. Health Psychol. 2014, 19, 393–408. [Google Scholar] [CrossRef]
  97. Martino, M.; Fedele, R.; Massara, E.; Recchia, A.G.; Irrera, G.; Morabito, F. Long-Term Safety of Granulocyte Colony-Stimulating Factor in Normal Donors: Is It All Clear? Expert Opin. Biol. Ther. 2012, 12, 609–621. [Google Scholar] [CrossRef]
  98. Glazier, A.K. The Principles of Gift Law and the Regulation of Organ Donation. Transpl. Int. 2011, 24, 368–372. [Google Scholar] [CrossRef]
  99. Domínguez-Gil, B.; Delmonico, F.L.; Shaheen, F.A.M.; Matesanz, R.; O’Connor, K.; Minina, M.; Muller, E.; Young, K.; Manyalich, M.; Chapman, J.; et al. The Critical Pathway for Deceased Donation: Reportable Uniformity in the Approach to Deceased Donation. Transpl. Int. 2011, 24, 373–378. [Google Scholar] [CrossRef]
  100. Kootstra, G.; van Heurn, E. Non-Heartbeating Donation of Kidneys for Transplantation. Nat. Clin. Pract. Nephrol. 2007, 3, 154–163. [Google Scholar] [CrossRef]
  101. Kootstra, G.; Daemen, J.H.; Oomen, A.P. Categories of Non-Heart-Beating Donors. Transplant. Proc. 1995, 27, 2893–2894. [Google Scholar]
  102. Limkemann, A.; Lindell, S.L.; Reichstetter, H.; Plant, V.; Parrish, D.; Ramos, C.; Kowalski, C.; Quintini, C.; Mangino, M.J. Donor Gluconate Rescues Livers from Uncontrolled Donation after Cardiac Death. Surgery 2016, 159, 852–861. [Google Scholar] [CrossRef]
  103. Larivière, S. Launch of the CINERGY Trial: Linking Donation and Transplantation. Available online: https://cdtrp.ca/en/launch-of-the-cinergy-trial/ (accessed on 29 December 2022).
Ijms 24 03518 g001 550
Figure 1. Cellular mechanisms of ischemia-reperfusion injury incurred through solid organ transplantation. The warm ischemia period begins with the interruption of perfusion to the donor organ and continues until the organ is flushed with hypothermic preservation solution, which marks the beginning of cold ischemia. The cold ischemic period typically consists of 4 °C cold storage of the procured organ and continues until the graft is implanted into the recipient. Together, these two ischemic periods lead to the generation of a pathological state that is included in the depletion of ATP due to the unavailability of oxygen, calcium accumulation, and decrease in cellular pH due to altered ion channel activity, and autophagy, which likely occurs to provide a source of energy. Subsequent reperfusion of the transplanted organ induces a paradoxical response whereby the injury is exacerbated. The restoration of blood flow rapidly restores pH levels and leads to the massive generation of reactive oxygen species (ROS), which together with the high intracellular calcium concentration can induce the opening of mitochondrial permeability transition pores (mPTP). Collectively, these effects can induce cell death, primarily via apoptosis and necrosis. Necrotic cell death releases danger-associated molecular patterns (DAMPs) into the extracellular space and leads to an inflammatory response. Figure created with BioRender.com.
Figure 1. Cellular mechanisms of ischemia-reperfusion injury incurred through solid organ transplantation. The warm ischemia period begins with the interruption of perfusion to the donor organ and continues until the organ is flushed with hypothermic preservation solution, which marks the beginning of cold ischemia. The cold ischemic period typically consists of 4 °C cold storage of the procured organ and continues until the graft is implanted into the recipient. Together, these two ischemic periods lead to the generation of a pathological state that is included in the depletion of ATP due to the unavailability of oxygen, calcium accumulation, and decrease in cellular pH due to altered ion channel activity, and autophagy, which likely occurs to provide a source of energy. Subsequent reperfusion of the transplanted organ induces a paradoxical response whereby the injury is exacerbated. The restoration of blood flow rapidly restores pH levels and leads to the massive generation of reactive oxygen species (ROS), which together with the high intracellular calcium concentration can induce the opening of mitochondrial permeability transition pores (mPTP). Collectively, these effects can induce cell death, primarily via apoptosis and necrosis. Necrotic cell death releases danger-associated molecular patterns (DAMPs) into the extracellular space and leads to an inflammatory response. Figure created with BioRender.com.
Ijms 24 03518 g001
Ijms 24 03518 g002 550
Figure 2. Molecular targets of H2S pre-treatment in cold and warm IRI. Hydrogen sulfide (H2S) pre-treatment regimens may protect against IRI by modifying different molecular targets. SOD: superoxide dismutase; Nrf2: nuclear factor erythroid 2-related factor 2; IL-10: interleukin-10; ROS: reactive oxygen species; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; IL-6: interleukin-6; TNF-α: tumor necrosis factor-alpha; CAT: catalase; GPx: glutathione peroxidase; GR: glutathione reductase; HO-1: heme oxygenase-1; NQO-1: NADPH quinone oxidoreductase-1; ETC: electron transport chain; PGC1-α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; K+ATP: adenosine triphosphate-sensitive potassium channel; Bcl2: B-cell lymphoma-2; ICAM-1: intercellular adhesion molecule-1; Bax: Bcl-2 associated X-protein. H2S is represented as a ball-and-stick model (sulfur in yellow; hydrogen in white; covalent bonds in grey). Figure created with BioRender.com.
Figure 2. Molecular targets of H2S pre-treatment in cold and warm IRI. Hydrogen sulfide (H2S) pre-treatment regimens may protect against IRI by modifying different molecular targets. SOD: superoxide dismutase; Nrf2: nuclear factor erythroid 2-related factor 2; IL-10: interleukin-10; ROS: reactive oxygen species; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; IL-6: interleukin-6; TNF-α: tumor necrosis factor-alpha; CAT: catalase; GPx: glutathione peroxidase; GR: glutathione reductase; HO-1: heme oxygenase-1; NQO-1: NADPH quinone oxidoreductase-1; ETC: electron transport chain; PGC1-α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; K+ATP: adenosine triphosphate-sensitive potassium channel; Bcl2: B-cell lymphoma-2; ICAM-1: intercellular adhesion molecule-1; Bax: Bcl-2 associated X-protein. H2S is represented as a ball-and-stick model (sulfur in yellow; hydrogen in white; covalent bonds in grey). Figure created with BioRender.com.
Ijms 24 03518 g002
Table
Table 1. Summary of the protective effects of exogenous H2S ischemic treatment and post-treatment in animal models of cold and warm IRI.
Table 1. Summary of the protective effects of exogenous H2S ischemic treatment and post-treatment in animal models of cold and warm IRI.
ModelH2S Treatment ModalityEffect of H2SReferences
Warm cerebral IRI in miceSTS administered one minute or one minute and daily for one week after reperfusion-Improved survival
-Improved neurological function		[43]
Warm hepatic IRI in miceNa2S administered during ischemia (five minutes before reperfusion)-Reduced liver injury
-Increased ratio of GSH to GSSG
-Increased protein expression of Trx-1, HSP-90, and Bcl-2
-Decreased protein expression of cleaved caspase-3
-Reduced lipid peroxidation		[44]
Warm intestinal IRI in miceNaHS administered during reperfusion-Increased mesenteric perfusion
-Reduced intestinal mucosal damage
-Decreased levels of IL-6, IL-9, IL-10, VEGF, FGF-2, MIP-1α, eotaxin, IP-10, MIP-2, G-CSF, KC in intestinal tissue
-Effects of H2S mediated through endothelial nitric oxide synthase		[45]
Warm myocardial IRI in miceNa2S administered during reperfusion-Reduced myocardial injury and infarct size
-Reduced level of IL-1β and apoptosis in cardiac tissue
-Increased cardiac function
-Reduced leukocyte infiltration
-Increased efficiency of ETC complexes I and II		[46]
Cold pancreatic IRI in pigsAP39 administered during ischemia (preservation solution supplemented with AP39)-Decreased ROS production
-Increased mitochondrial membrane polarization
-Increased ATP production
-Decreased expression of IL-1β and TNF-α
-Improved islet function in recipient mice following xenogeneic transplantation		[47]
Cold pulmonary IRI in rabbits (ex vivo)NaHS administered during reperfusion-Decreased ROS production[48]
Cold renal IRI in ratsNaHS administered during ischemia (preservation solution supplemented with NaHS)-Improved recipient survival and renal function
-Reduced renal tissue apoptosis and necrosis
-Reduced leukocyte infiltration and expression of IFN-γ and ICAM-1		[49]
Warm renal IRI in miceNaHS administered daily beginning two days after reperfusion-Reduced renal tubule damage
-Improved renal function and recovery of recipient body weight
-Increased tubular epithelial cell and decreased interstitial cell proliferation
-Reduced renal fibrosis
-Decreased ROS production, ratio of GSSG to GSH, and Nox4 expression
-Increased MnSOD and catalase expression		[50]
Warm renal IRI in ratsAP39 administered during ischemia-Improved renal function
-Decreased ROS production
-Decreased neutrophil infiltration and IL-12 levels
-Decreased apoptosis		[51]
Cold renal IRI in ratsSTS administered during ischemia (preservation solution supplemented with STS)-Improved recipient survival and renal function
-Decreased apoptosis and necrosis
-Decreased KIM-1, IFN-γ, TNF-α, IL-6, Bax, Caspase-3, and JNK2 expression
-Increased PGC-1α, NDUFB8, SDHB, ERK1, and ERK2 expression
-Decreased macrophage and neutrophil infiltration 		[15]
Cold renal IRI in ratsAP39 administered during ischemia (preservation solution supplemented with AP39)-Improved recipient survival and renal function [52]
GSH: reduced glutathione; GSSG: oxidized glutathione; Trx-1: thioredoxin-1; 90-kDa heat shock protein (HSP-90); Bcl-2: B-cell lymphoma-2; IL-6: interleukin-6; IL-9: interleukin-9; IL-10: interleukin-10; VEGF: vascular endothelial growth factor; FGF-2: fibroblast growth factor 2; MIP-1α: macrophage inflammatory protein-1 alpha; IP10: C-X-C ligand 10; MIP-2: macrophage inflammatory protein 2; G-CSF: granulocyte-colony stimulating factor; KC: C-X-C ligand 1; IL-1β: interleukin-1 beta; ETC: electron transport chain; ROS: reactive oxygen species; ATP: adenosine triphosphate; TNF-α: tumor necrosis factor-alpha; IFN-γ: interferon gamma; ICAM-1: intercellular adhesion molecule-1; Nox4: NADPH oxidase 4; MnSOD: manganese superoxide dismutase; IL-12: interleukin-12; KIM-1: kidney injury molecule-1; Bax: Bcl-2 associated X-protein; JNK2: c-Jun N-terminal kinase 2; PGC-1α: Pparg coactivator 1 alpha; NDUFB8: NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8; SDHB: succinate dehydrogenase [ubiquinone] iron-sulfur subunit; ERK1: mitogen-activated protein kinase 1; ERK2: mitogen-activated protein kinase 2.
Table
Table 2. Summary of protective effects of exogenous H2S pre-treatment in animal models of cold and warm IRI.
Table 2. Summary of protective effects of exogenous H2S pre-treatment in animal models of cold and warm IRI.
ModelH2S Pre-Treatment ModalityEffect of H2SReferences
Cold pulmonary IRI in rabbitsInhalation of H2S for 2 h prior to procurement-Better pulmonary function in recipient
-Lower ROS production following reperfusion		[53]
Cold pulmonary IRI in ratsInflation of procured lung with H2S for 2 h before SCS-Reduced apoptosis, inflammation, and oxidative stress
-Reduced NF-kB nuclear localization
-Increased Nrf2 nuclear localization		[56]
Warm renal IRI in miceInhalation of H2S for 30 min prior to ischemia-Reduced impairment of kidney function, apoptosis, inflammation, and degree of structural damage
-Attributed protective effect to hypometabolism induced by H2S		[61]
Warm renal IRI in ratsNaHS administered 10 min before ischemia-Reduced levels of plasma creatinine, blood urea nitrogen, renal malondialdehyde concentration, and increased superoxide dismutase activity[62]
Warm renal IRI in ratsNaHS administered daily for 35 days before ischemia-Decreased NF-kB concentration
-Downregulation of ICAM-1 expression		[63]
Warm renal IRI in miceGYY4137 administered for 2 consecutive days before ischemia-Elevated Nrf2 nuclear translocation[64]
Warm myocardial IRI in ratsNaHS administration 15 min prior to ischemia-Reduced infarct size
-Reduced apoptosis, caspase 9 activity, NF-kB nuclear translocation, oxidative stress, myeloperoxidase activity, and neutrophil infiltration		[68]
Warm myocardial IRI in ratsNaHS administered 1 day before ischemia-Cardioprotection through a PKC-dependent mechanism
-Pre-treatment provided a greater protective effect than post-treatment		[69]
Warm myocardial IRI in db/db miceNa2S administered 24 h or daily injection for 7 days before ischemia -Infarct size relative to area at risk was reduced in both treatment regiments compared to vehicle control, but was 51% more effective in 7 day treatment than acute treatment.[71]
Warm myocardial IRI in rat heart (ex vivo)STS administration 15 min before ischemia-Reduced apoptosis and ROS levels.
-Preserved mitochondrial function		[80]
Warm myocardial IRI in rat heart (ex vivo)STS administration 15 min before ischemia-Improved activity of ETC complexes I-IV
-Elevated PGC1α expression		[81]
Warm myocardial IRI in rat heart (ex vivo)STS administration 15 min before ischemia-Protective effects abolished in the presence of PI3K/mTOR/KATP inhibitors[82]
Warm hepatic IRI in ratsNaHS administration 5 min before ischemia-Reduced necrosis, mitochondrial-related cell death and apoptosis
-Inhibited mPTP opening and activation of Akt-GSK-3β signaling		[73]
Warm hepatic IRI in miceNaHS administration 30 min before ischemia-Reduced expression of TNF-α and IL-6
-Reduced apoptosis through inhibiting JNK1 signaling 		[74]
Warm intestinal IRI in ratsNaHS administered 24 h before ischemia-Prevented postischemic mitochondrial dysfunction) in a BKCa channel-dependent manner
-Reduced leukocyte rolling and adhesion in postischemic intestine		[77]
Warm pulmonary IRI in ratsGYY4137 administered 1 h before ischemia-Promoted Nrf2/HO-1 and eNOS-mediated antioxidant signaling pathways.[79]
ROS: reactive oxygen species; NF-κB: nuclear factor kappa B; Nrf2: nuclear factor erythroid 2–related factor 2; ICAM-1: intercellular adhesion molecule 1; PKC: protein kinase C; ETC: electron transport chain; PGC1α: peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PI3K: phosphoinositide 3-kinase; mTOR: mammalian target of rapamycin; KATP: ATP-sensitive potassium; mPTP: mitochondrial permeability transition pore; Akt: protein kinase B; GSK-3β: glycogen synthase kinase-3 beta; TNF-α: tumor necrosis factor-alpha; IL-6: interleukin-6; JNK1: c-Jun N-Terminal Protein Kinase 1; BKCa channel: calcium-activated, large conductance potassium channel; HO-1: heme oxygenase-1; eNOS: endothelial nitric oxide synthase.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

McFarlane, L.; Nelson, P.; Dugbartey, G.J.; Sener, A. Pre-Treatment of Transplant Donors with Hydrogen Sulfide to Protect against Warm and Cold Ischemia-Reperfusion Injury in Kidney and Other Transplantable Solid Organs. Int. J. Mol. Sci. 2023, 24, 3518. https://doi.org/10.3390/ijms24043518

AMA Style

McFarlane L, Nelson P, Dugbartey GJ, Sener A. Pre-Treatment of Transplant Donors with Hydrogen Sulfide to Protect against Warm and Cold Ischemia-Reperfusion Injury in Kidney and Other Transplantable Solid Organs. International Journal of Molecular Sciences. 2023; 24(4):3518. https://doi.org/10.3390/ijms24043518

Chicago/Turabian Style

McFarlane, Liam, Pierce Nelson, George J. Dugbartey, and Alp Sener. 2023. "Pre-Treatment of Transplant Donors with Hydrogen Sulfide to Protect against Warm and Cold Ischemia-Reperfusion Injury in Kidney and Other Transplantable Solid Organs" International Journal of Molecular Sciences 24, no. 4: 3518. https://doi.org/10.3390/ijms24043518

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop